- Home
- LVLU vs HOWL Comparison
LVLU vs HOWL Comparison
Compare LVLU & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | HOWL |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 30.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LVLU | HOWL |
|---|---|---|
| Price | $15.90 | $0.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $15.00 | $5.00 |
| AVG Volume (30 Days) | 17.1K | ★ 384.5K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $315,887,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $0.53 |
| 52 Week High | $32.32 | $2.23 |
Technical Indicators
Market Signals| Indicator | LVLU | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 59.04 |
| Support Level | $14.68 | $0.81 |
| Resistance Level | $16.25 | $1.03 |
| Average True Range (ATR) | 1.37 | 0.08 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 70.85 | 74.89 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.